Evaluation and Modeling with the Therapeutic Effects Group
Members
Maîtresse de conférences - praticienne hospitalière
UCBL
Tel: 04 72 11 94 07
Maître de conférences - praticien hospitalier
UCBL
Tel: 33 04 72 32 34 87
Professeur des universités - médecin généraliste
UCBL
Tel: 04 78 74 18 18
Maîtresse de conférences
UCBL
Tel: 33 04 78 78 57 83
Professeure des universités - médecin généraliste
UCBL
Tel: 04 78 77 72 86
Professeur d'université - praticien hospitalier
UCBL
Tel: 04 72 44 81 42
Doctorante
HCL
Assistant hospitalier universitaire
UCBL
Doctorant
UCBL
Tel: 04 72 44 81 42
Professeur d'université - praticien hospitalier
UCBL
Tel: 33 04 72 16 80 99
Doctorante
autre
Tel: 04 72 44 81 42
Praticien hospitalier
HCL
Tel: 04 72 44 81 42
Professeur d'université - praticien hospitalier émérite
UCBL
Professeur d'université - praticien hospitalier
UCBL
Tel: 04 27 85 77 32
Professeur d'université - praticien hospitalier
UCBL
Tel: 33 04 78 86 33 01
Post-doc
UCBL
Maîtresse de conférences - praticienne hospitalière
UCBL
Maître de conférences - praticien hospitalier
UCBL
Tel: 04 72 11 94 20
Doctorante
UCBL
Professeur d'université - praticien hospitalier
UCBL
Tel: 33 04 72 12 94 37
Post-doc
UCBL
Doctorante
UCBL
Tel: 04 72 44 81 42
EMET presentation
The EMET team brings together doctors, pharmacists and research professors specializing in the evaluation and use of drug and non-drug therapies, around a single project built on two axes:
- the evaluation of therapies in clinical trials or observational studies;
- the construction of explanatory and predictive models, to better understand and therefore predict the effect of therapies, simulate their impacts at the individual and population level, and improve the innovation paradigm.
The EMET team is therefore part of two major dynamics in therapy: analysis of the level of evidence and precision medicine.
The fields of application are cardiovascular and metabolic diseases, primary care medicine, rare pediatric diseases (including genetic and autoimmune diseases), oncology and infectious diseases.
EMET members implement approaches using different mathematical models: direct comparison and network meta-analysis, pharmacokinetic/pharmacodynamic analysis, Bayesian networks and machine learning.
Education
The EMET team is specially involved in the teaching of pharmacology and therapeutics and the modeling of the treatment effect through the coordination of the Masters 2 Clinical Evaluation (EC) and Pharmacology modeling and clinical trials (PHAME), Interpretation of Therapeutic Trials (IET), Training of investigators in clinical drug trials (FIEC) and Training of clinical research assistants and clinical study technicians (FARCTEC). Teacher-researchers are also involved in the first (pharmacology), second (pharmacology / therapeutics, pharmacy) and third cycles (general medicine, pediatrics, internal medicine) in health training courses.
Society involvement
The members of the EMET team through their work and their interactions with the other components of the LBBE, National societies, governmental (HAS) or international (EMA) agencies, and the Hospices Civils de Lyon, are invested in current societal issues: rationalization of the use of health product resources, research ethics, gender equality, rationality of approaches in analyzing the diversity of human populations.
Publications
Display of 31 to 60 publications on 613 in total
Prolonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study
Blood .
Journal article
see the publicationImmune thrombocytopenia and pregnancy: an exposed/nonexposed cohort study
Blood . 141 ( 1 ) : 11-21
Journal article
see the publicationGranulocyte-macrophage colony-stimulating factor (GM-CSF) in patients presenting sepsis-induced immunosuppression: The GRID randomized controlled trial
Journal of Critical Care . 78 ( 1 ) : 154330
DOI: 10.1370/afm.2908
Journal article
see the publication[Does aspirin have a place in primary cardiovascular prevention by the polypill ? Simulation study on a realistic virtual population].
Therapies . 78 ( 6 ) : 667-678
Journal article
see the publicationImplementation of a centralized pharmacovigilance system in academic pan‐European clinical trials: Experience from EU‐Response and conect4children consortia
Therapies . 78 ( 5 ) : S11-S18
Journal article
see the publicationPharmacokinetic/pharmacodynamic model of a methionine starvation based anti-cancer drug
Medical and Biological Engineering and Computing . 61 ( 7 ) : 1697-1722
Journal article
see the publicationDiabetes, periodontitis, and cardiovascular disease: towards equity in diabetes care
Frontiers in Public Health . 11 ( 1 ) : 1270557
Journal article
see the publicationPharmacokinetic/pharmacodynamic model of a methionine starvation based anti-cancer drug
Medical and Biological Engineering and Computing . 61 ( 7 ) : 1697-1722
Journal article
see the publicationProject Rebuild the Evidence Base (REB): a method to interpret randomised clinical trials and their meta-analysis to present solid benefit-risk assessments to patients
Therapies . 78 ( 4 ) : 353-365
Journal article
see the publicationEditorial: New insights into caring for pediatric patients with cystic fibrosis
Frontiers in Pediatrics . 11
Journal article
see the publicationL’aspirine a-t-elle une place dans la prévention cardiovasculaire primaire par la polypill ? Étude de simulation sur une population virtuelle réaliste
Therapies . 78 ( 6 ) : 667-678
Journal article
see the publicationAssociation between immune‐related adverse events and prognosis in patients treated with immune checkpoint inhibitors in melanoma: A surrogacy analysis
Fundamental & Clinical Pharmacology . 38 ( 2 ) : 369-379
DOI: 10.1111/fcp.12966
Journal article
see the publicationHeart and systemic sclerosis—findings from a national cohort study
Rheumatology .
Journal article
see the publicationHeart and systemic sclerosis—findings from a national cohort study
Rheumatology .
Journal article
see the publicationIncidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observatio
RMD Open . 9 ( 3 ) : e003064
Journal article
see the publicationCirculating microRNAs improve bacterial infection diagnosis and overall survival prediction in acute decompensation of liver cirrhosis
iScience . 26 ( 8 ) : 107427
Journal article
see the publicationPlatelet count threshold for hemorrhage in patients with immune thrombocytopenia treated with antiplatelet agents.
Blood .
Journal article
see the publicationPatients’ perceptions on clinical trials outcomes in pulmonary arterial hypertension therapy
Thorax . 78 ( 7 ) : 721-725
Journal article
see the publicationCirculating microRNAs improve bacterial infection diagnosis and overall survival prediction in acute decompensation of liver cirrhosis
iScience . 26 ( 8 ) : 107427
Journal article
see the publicationTreatment strategy for acquired pure red cell aplasia: a systematic review and meta-analysis
Blood Advances . 7 ( 21 ) : 6451-6465
Journal article
see the publicationPlatelet count threshold for hemorrhage in patients with immune thrombocytopenia treated with antiplatelet agents
Blood . 142 ( 12 ) : 1099-1101
Journal article
see the publicationProlonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study
Blood .
Journal article
see the publicationImmune thrombocytopenia and pregnancy: an exposed/nonexposed cohort study
Blood . 141 ( 1 ) : 11-21
Journal article
see the publicationAUC-based monitoring and model-informed precision dosing of vancomycin in critically ill patients: why and how?
Anaesthesia Critical Care & Pain Medicine . 42 ( 6 ) : 101286
Journal article
see the publicationPopulation Pharmacokinetics of Vancomycin in Patients Receiving Hemodialysis in a Malian and a French Center and Simulation of the Optimal Loading Dose
Therapeutic Drug Monitoring . 45 ( 5 ) : 637-643
Journal article
see the publicationEvaluation of Limited Sampling Strategies for Bayesian Estimation of Daptomycin Area Under the Concentration–Time Curve: A Short Communication
Therapeutic Drug Monitoring . 45 ( 4 ) : 562-565
Journal article
see the publicationFrom Personalized to Precision Medicine in Oncology: A Model-Based Dosing Approach to Optimize Achievement of Imatinib Target Exposure
Pharmaceutics . 15 ( 4 ) : 1081
Journal article
see the publicationSuboptimal exposure to fluconazole in critically ill patients: Pharmacokinetic analysis and determinants
Infectious Diseases Now . 53 ( 2 ) : 104630
Journal article
see the publicationEvaluation of Renal Impairment Influence on Metabolic Drug Clearance using a Modelling Approach
Clinical Pharmacokinetics . 62 ( 2 ) : 307-319
Journal article
see the publicationGranulocyte-macrophage colony-stimulating factor (GM-CSF) in patients presenting sepsis-induced immunosuppression: The GRID randomized controlled trial
Journal of Critical Care . 78 : 154330
Journal article
see the publication
You also, comment on this article